AUS
NZ
UK
CA
USA
IND
Highlights
Achieved record revenue in FY2025
Strong US market contracts drive performance
Margins reached highest level to date
Pro Medicus posted record-breaking results for FY2025, reinforcing its position as one of the notable performers within the ASX200 group. The medical imaging software provider delivered substantial increases in both revenue and , supported by sustained operational momentum and the successful execution of major contracts. These results reflect the company’s ability to maintain growth while extending its market presence, particularly in international markets.
Strong Half-Year Momentum
The second half of FY2025 demonstrated the company’s continued operational strength, with both underlying and statutory margins reaching new highs. While the pace of growth was slightly moderated compared to prior periods, Pro Medicus (ASX:PME) maintained a solid upward trajectory. Operational efficiencies and cost control contributed to stable, reflecting a balanced performance across business divisions.
Expansion Through Major US Contracts
The company’s performance was significantly bolstered by its US operations, which accounted for a large share of revenue growth. The long-term agreement with Trinity Health marked one of the year’s most notable milestones, followed by a substantial deal with UCHealth in Colorado. These multi-year contracts provided a steady revenue stream and positioned Pro Medicus as a key technology partner for large healthcare networks in North America.
Position Within the ASX200 Group
Being part of the ASX200 highlights Pro Medicus’ market relevance and scale. The company’s ability to win and deliver on large contracts has elevated its standing in both domestic and international markets. Its strong balance sheet and operational model provide the foundation for continued expansion, supported by a growing pipeline of in the healthcare technology sector.
Future Direction of Global Operations
While future market conditions will influence operational performance, Pro Medicus’ established track record and international presence place it in a competitive position within the ASX200 group. The combination of stable margins, recurring revenue from long-term contracts, and a focus on innovation provides a solid base for ongoing growth. The company’s ability to adapt to evolving healthcare needs ensures it remains a relevant and competitive player on the global stage.
Frequently Asked Questions
- What is Pro Medicus’ primary business focus?
Pro Medicus specialises in medical imaging software solutions, serving hospitals, clinics, and health networks. - Which markets contribute most to Pro Medicus’ results?
The United States market plays a significant role, driven by long-term contracts with major healthcare providers. - Is Pro Medicus part of the ASX200 index?
Yes, Pro Medicus is included in the ASX200 index, reflecting its scale and market capitalisation.
